14:43 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies identified a pyrimidinone-based inhibitor of TLR4 that could help treat MI. Chemical synthesis and screening of peptidomimetic analogs of a previously identified TLR4 inhibitor peptide in...
17:54 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
19:01 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; pancreatic cancer In vitro , cell culture and mouse studies identified a piperidinylimidazothiadiazole-based FER inhibitor that could help treat colorectal and pancreatic cancers. Screening of a small molecule library in a cell-based...
07:00 , Jun 2, 2016 |  BC Innovations  |  Translation in Brief

Finding the door

A team of U.S. and Israeli researchers has developed a high throughput assay that could solve a bottleneck in anti-infectives development: identifying the host cell receptors that pathogens use to gain entry. High throughput screens...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

Neurology INDICATION: Addiction Rat studies suggest DNMT1 inhibitors could help treat cocaine addiction. In a rat model of cocaine addiction and withdrawal, DNA methylation of multiple genes in the nucleus accumbens increased during cocaine withdrawal...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Purinergic receptor P2Y G protein-coupled 1 (P2RY1; P2Y1) Cell culture studies identified dual-acting antioxidant and P2Y1 receptor agonist nucleotides that could be useful...
08:00 , Dec 17, 2012 |  BioCentury  |  Strategy

Teva's puzzle pieces

Teva Pharmaceutical Industries Ltd. 's new management expects to achieve organic, profitable growth by globalizing key operating functions to reshape its cost structure while regionally tailoring its product offerings and using business development to amass...
07:00 , Oct 4, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Zebrafish model for narcolepsy A zebrafish model for narcolepsy could be used to identify new targets or therapeutic leads for the sleep disorder. In zebrafish,...
07:00 , Apr 15, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma Purinergic receptor P2Y G-protein coupled 1 (P2RY1; P2Y1) In vitro and rabbit studies identified a methylene and ATP-based agonist of P2Y1 that...
07:00 , Jul 18, 2005 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Innodia Inc. Laval, Quebec Technology: Small molecules to treat and prevent Type II diabetes Disease focus: Metabolic Clinical status: Phase Ib Founded: 2002 by Claude Vezeau and Francois Mongrain University collaborators: McGill University , Bar-Ilan...